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S_nary meso-Tetra(hydroxypbenyl)chlonn (mTHPC) is an attractive second-generation dihydroporphyrin
photosensitiser for use in photodynamic therapy. In this study, 1.3 mgkg-' body weight mTHPC was
administered intravenously, and laser-induced fluorescence was used to characterse and compare its localisa-
tion and retention in different rat tissues, including an induced experimental adenocarcinoma, 24 h and 48 h
post injection. These studies were performed in an attempt to predict the anatomical locations where mTHPC
PDT might be most effective and suggest suitable injection-irradiation intervals in each case. Of particular
interest were the intra-abdominal and intrathoracic tissues. The fluorescence was induced at 405 rum and the
fluorescence spectrum in the region 450-750 nm was analysed. All colected spectra were dominated by the
fluorescence signature of mTHPC with its peak at 652 nm, and all values in this study are in terms of
background-free drug-specific fluorescence intensity at that wavelength. The photosensitiser accumulated in
high concentrations in the tumour and the reticuloendothehal system. Muscular organs, such as the heart and
the abdominal wall, were charactesed by a low drug flurescence signature.
Photodynamic therapy (PDT) involves the administration of
a photosensitiser that is retained with some selectivity in
tumour tissue when compared with the surrounding tissue.
After a specific time interval, the tumour is illuminated with
light of an appropriate wavelength. This brings about the
photoactivation of the sensitiser in the tumour and the
generation of singlet oxygen and other cytotoxic free radicals
(Foote, 1982).
Recently, much attention has been directed towards the
use of PDT as an adjuvant to surgery in the management of
a number of advanced intracavitary malignancies. Here, max-
imal debulking surgery of the tumour is coupled with intra-
operative PDT of the tumour bed or the whole cavity in the
hope of delaying or even totally preventing local recurrence.
Clinical trials investigating adjuvant intraoperative PDT
(AIOPDT) in the management of pleural malignancies (Pass
et al., 1990; Ris et al., 1993), retroperitoneal sarcomas (Nam-
bisan et al., 1988), peritoneal carcinomatosis (Sindelar et al.,
1991) and other disseminated intraperitoneal tumours (De-
Laney et al., 1993) have been encouraging. Among the prob-
lems typical for AIOPDT are large surface areas (requiring
long irradiation periods under strict time limitations) and
difficult irradiation geometries (making dose calculations sub-
stantially more difficult).
So far a haematoporphyrin derivative, Photofrin, has been
used, almost exclusively, as the photosensitiser in clinical
PDT. Now, a second generation of photosensitiser is emerg-
ing, with improved properties for PDT. One such sensitiser is
meso-tetra(hydrophenyl)chlorin (mTHPC) (Figure 1). Unlike
haemotoporphyrin derivative, it has been custom designed
for use specificaly in PDT. Much work has been dedicated
to the development and testing of this compound (Beren-
baum et al., 1986; Bonnett & Berenbaum, 1989; Morgan,
1992; Braichotte et al., 1992; Ris et al., 1993), proving it to
be an effective photosensitiser for use in PDT. It has a
number of advantages over Photofrin, especially in relation
to AIOPDT. Its absorption band is more towards the red
region of visible light (652 nm), offering a deeper PDT effect
than Photofrin. mTHPC has a high rate of photobleaching.
The advantage of using a highly photobleachable sensitiser,
provided it does not produce toxic photoproducts on bleach-
ing, arises at threshold levels, at which the sensitiser level in
normal tissues is low enough to be totally bleached before it
can induce any necrosis. Thus, when using a highly photo-
bleachable sensitiser, precise light dosimetry is not essential
(Mang et al., 1987; Potter et al., 1987). This is of significance
when treating areas with difficult radiation geometries such
as those encountered in AIOPDT. Furthermore, mTHPC has
a high extinction coeffient, which would mean a reduction
in the irradiation time needs, good tumour selectivity and
only moderate skin sensitisation (Ris et al., 1991).
Apart from the photophysical properties of a photosen-
sitising drug for PDT, the pharmacokinetics, or the tissue
distribution of the drug as a function of time after adminis-
tration, is of particular importance. Well-defined, standar-
dised experimental models are necessary in order to compare
these properties with those of other sensitisers.
In this paper, we use laser-induced fluorescence (LIF)
measurements, as part of a standard protocol, to characterise
and compare the localisation and retention of mTHPC in
different rodent tissues at two time intervals of interest for
PDT. Similar studies have been previously carried out at our
laboratories, using the same tumour model, on other photo-
sensitisers, e.g. HpD (Ankerst et al., 1984; Svanberg et al.,
1986), polyhaematoporphynn ester (PHE), tetrasulphonated
HO
Figwe I Structure formula ofmeso-tetra(hydroxyphenyl)chlorin.
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phthalocyanine (TSPc) (Andersson-Engels et al., 1989), and
benzoporphyrin derivative-monoacid (BPD-MA) (Anders-
son-Engels et al., 1993).
Material and mods
Two groups of rats, each consisting of three white inbred
male Wistar/Furth rats, were inoculated subcutaneously on
both hind legs with syngeneic tumour cells prepared from a
colon adenocarcinoma as descibed by Hedlund and Sjogren
(1980). Ten days after inoculation, at the time of intravenous
drug injection, each rat weighed about 240 g and the dia-
meter of each of the tumours ranged from 9 to 14 mm.
Before injection, mTHPC (Scotia Pharmaceutials, Guild-
ford, UK) was dissolved in 20% ethanol, 30% polyethylen
glycol 400 and 50% water. The rats then received a dose of
1.3 mg kg-' body weight mTHPC. One group ofanimals was
kilLed 24 h post injection while the other group was kicLed
48 h post injection. The animals were killed by carbon diox-
ide inhalation. In order to avoid interference from the highly
fluorescent white fur, the hair on both hind legs and on the
abdomen of the animals was shaved off. The tumour and
surrounding muscle were exposed by removing the covenng
skin. The fluorescence was then measured in a superficial
scan from the muscle fascia across the tumour and over to
the muscle on the other side. Following this, a longitudinal
incision in the tumour and surrounding muscle was made
and an interstitial scan performed. In performing tumour
scans, measurements were taken at points equally spaced
along a line bisecting the tumour. In the healthy muscle on
both sides of the tumour, measurements were performed at
points 10, 5 and 2 mm from the tumour-muscle border.
Inside the tumour, 3-5 measurements were taken, the first
and last points being about 2 mm from the border of the
tumour. In addition, measurements were performed on the
tumour-muscle border. At the time of meaurment the
majority of tumours had developed necrotic areas mostly
located in the tumour centre. While taking measurements,
areas of necrosis were avoided and thus influences by tissue
necrosis were minimised. In spite of this, the existence of
small necrotic regions may have contributed to the larger
sandard deviations of the fluorescence signals from tumour
tissue, especially those taken interstitialy and at 48 h post
injection.
After tumour scans had been performed on each of the
two tumours in the animal, the different inner orgns were
investigated. The abdomen was cut open and the optical fibre
placed in contact with the different tissues in situ. In the case
of the urinary bladder and the trachea, the organs were cut
open and the measurements performed on the mucosal sur-
faces.
Equipment
The optical set-up used for the recording of laser-induced
fluorescence is similar to the one previously described by
Andersson-Engels et al. (1991). Excitation light at 405 nm
was produced by a compact dye laser (Laser Sciec
DLM220), which was pumped by a nitrogen laser (Laser
Science VSL-337ND). The laser light was transmitted
through a 600 am optical fibre, which was held in contact
with the tissue under investigation. The fluoresence light was
tansmitted back via the same fibre, through a dichroic mirror,
and was focused on the lOO1pm entrance slit of a polychro-
mator (Acton SP-275). The dichroic mirror, in addition to a
455 nm cut-off filter, served to block out any rlted excita-
tion light. The wavelength-dispersed light was captured by an
image-intensified charge-coupled device (CCD) camera cool-
ed to -20 C (Princeton Instruments). The obtained spectra
were spectrally corrected for the non-uniform efficiency in the
detection using a calibrated black-body radiator. The record-
ed spectra, each of which integrates the total fluorescence
produced from 50 laser pulses, were stored on computer
disks for subsequent analysis.
Resuts and discios
In Figure 2, a laser-induced fluorescence spectrum recorded
e.x vivo from the surface of the thigh muscle of a rat injected
24h earlier with 1.3 mgkg-' mTHPC is shown. This spec-
trum, like all other spectra obtained in this study, is
dominated by the fluorescence signature of mTHPC, charac-
terised by two peaks at approximately 652 nm and 718 nm.
As illustrated in the figure, the fluorescence intensities at the
two peaks were evaluated with the tissue autofluorescence
subtracted, and the free-standing peaks at 652 nm and
718 nm were designated 'A' and 'C' respectively. The ratio
between the main peak at 652 nm (A) and the second peak at
718nm (C) was consistently 10:1, irrespective of the tissue
type or the time interval investigated. The broad peak
around 490 nm (B) orginates from endogenous tissue fluoro-
phores.
In Figure 3, the spectra obtained from a scan performed
across the surface of a tumour and the surrounding, non-
diseased muscle are shown. As can be seen, the dual-peaked
substance-related fluorescence is much stronger from the
points recorded from the tumour, including the border zone,
than from the points recorded from muscle tissue. This
indicates a higher sensitiser concentration in the tumour
tissue than in the healthy surrounding tissue. The auto-
fluorescence shows an insignificantly low intensity through-
out the scan. The evaluated data from two other scans are
shown in Figure 4. The scan represented in Figure 4(ii),
which is from a rat injected with mTHIPC 48 h earler, shows
good tumour-muscle demarcation. However, the absolute
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Fge 2 Laser-induced fluorescence spectrum recorded ex vivo
from the surface of the thigh muscle of a rat injected 24 h earlier
with 1.3 mgkg-' mTHPC. The spectrum is dominated by the
fluorescence signature of mTHPC, charactersed by two peaks at
approximately 652 nm (A) and 718 nm (C). The tissue
autofluorescence at 490 nm (B) is also indicated. The fluoresence
intensities at A and C we evaluated with the autofluorescence
background subtracted, as marked in the figure. Note that, des-
pite the low concentration of the sensitiser in musce when com-
pared with the other tissues investigated, the intensity of the
drug-specific peak (A) is approximately ten times that of the
autofluorescence (B).
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Fuge 3 Fluorescence emission spectra obtained from a scan performed across the surface of a tumour and the surrounding,
healthy muscle. 24 h after the administration of 1.3 mg kg' mTHPC.
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Fu_we 4 The fluorescence intensities at 652 nm ( M ) (A) (left
axis) and 718 nm (L ) (C) (right axis) in relative units for two
tumour scans. The scan in a is 24 h post i.v. injection whereas the
scan in b is 48 h post i.v. injection. Note that the overall
fluorescence intensities for the points in a are much higher than
those in b. Note also the dramatic drop in fluorescence intensity
associated with necrosis. The relationship between the two drug-
related peaks is constant throughout both scans.
fluorescence intensities of measurements are much lower than
similar points in Figure 4(i) (24 h). Also of interest is the
dramatic decrease in fluorescence intensity in the measure-
ment corresponding to an area designated by naked eye to be
necrotic. Such necrotic areas, which were the result of
endogenously induced degeneration of the tumour, as justi-
fied by similar degrees of necrosis in the control rats, were
slightly more common in the tumours investigated 48 h post
injection than those investigated after 24 h. The spectra taken
from the necrotic areas were characterised by a drop in
intensity when compared with spectra recorded from viable
tumour tissue. The necrosis also predisposed to haemorr-
hages, which further interfered with the fluorescence because
of light absorption by blood. These points were generally
avoided during measurements and during statistical analysis
and thus had little impact on the results.
In Figure 5 the evaluated data from all the tumour scans
are summarised. The scans are grouped according to the time
interval after injection and, further, into surface scans and
interstitial scans. Each group of scans is represented in terms
of the mean background-free substance-related fluorescence
intensity, A [I (652 nm)], for each point, expressed in units
relative to a fluorescence standard. The average values from
each of the points are plotted together with error bars (each
indicating ± 1 standard deviation). The data in the figure
clearly show that the main fluorescence peak at 652 nm has a
higher intensity in temour than in the surrounding muscle.
On average, the tumour demarcation relative to muscle is
about 9:1 24 h post injection and 7:1 48 h post injection. The
later measurements (48 h) and those taken interstitially
generally showed lower fluorescence intensities and larger
standard deviations than those taken at 24 h and from sur-
face scans. This is possibly a result of necrosis and blood
interference, as discussed above, leading to fluctuations in the
fluorescence signal. Alternatively, lower fluorescence from the
central portion of tumours compared with the outer surface
may be due to higher uptake and retention by the more
vascular tumour capsule. The definition of measurement
points as 'tumour' and 'healthy muscle' were made by un-
aided naked eye judgements. This would explain the large
variation in the intensities of fluorescence measurements
taken at points 2 mm outside of the tumour, i.e. these areas
could possibly be infiltrated by the tumour though not evi-
dent by mere naked-eye examination. These points were
accordingly disregarded when calculating the average tumour-
muscle demarcation and thus did not have any significant
effect on the final results.
Data concerning the uptake and retention of mTHPC by
the different types of tissue included in this study, estimated
by means of ex vivo laser-induced fluorescence, at time points
24 and 48 h after the intravenous injection, are presented in
Figures 6 and 7. At 24 h post injection, the tumour surface
exhibited the highest mTHPC fluorescence intensity, A [I
(652 nm)l, of all the tissues investigated in this study. Other
tissues that exhibited similarly high fluorescence intensity at
24 h were small intestine, liver, lung and tumour interior. The
intensity of the chlorin-related fluorescence for all inves-
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tigated tissues was significantly lower at 48 h post injection
than at 24 h. The signal at 48 h ranged from a maximum of
55% of the corresponding 24 h level to a minimum of 7%.
The highest percentage retention at 48 h, as compared with
24 h, was found in skeletal muscle, trachea and the tumour
interior. These tissues demonstrated a drug-related fluo-
rescence intensity 48 h post injection that was approximately
50% of the corresponding signal at 24 h. In general, and with
the exception of the urinary bladder, all the muscular tissues
studied (i.e. skeletal muscle, abdominal wall and heart) were
characterised by relatively low initial (24 h) signals, and
retained at 48 h post injection a relatively large portion
(30-50%) of their initial chlorin share. The fluorescence
measurements on the urinary bladder were performed on the
mucosa of the organ. The sensitiser content of the mucosa
could be influenced by that of the urine.
In contrast to the tumour tissue, the fluorescence inten-
sities in the liver, lung and spleen, which at 24 h post injec-
tion were similar to those of the tumour tissue, dropped
rapidly over the ensuing 24 h. At 48 h post injection, these
tissues exhibited signal intensities only 7-14% of their initial
value (24 h), whereas the tumour retained 48% of its 24 h
level. This rapid elimination of drug from these tissues could
suggest a different mechanism of accumulation and/or elimin-
ation than that prevalent in the tumour tissue. The high
concentration in the liver, and the fact that the sensitiser
disappears quite rapidly over the ensuing 24 h, may indicate
a relatively rapid drug metabolism in this organ. In this case,
the high fluorescence intensity in the proximal part of the
intestinal system is in good agreement with the high liver
intensity. Alternatively, it could be that the aggregates of
mTHPC are initially trapped in the extensive microvascula-
ture of the liver, either passively or actively by the reticulo-
endothelial cells. The chlorin is washed away quite rapidly
over the ensuing 24 h. This argument could also contribute
to explaining the similar fluorescence intensity/retention pat-
terns obtained from the lungs and spleen. At 48 h post
injection, the tumour tissue, both tumour interior and
tumour surface, expressed fluorescence intensities much
higher than those of the other organs. The values for these
organs have already been discussed above.
Each type of sensitising molecule has its own pattern of
distribution in tissue. However, it seems that many sensitisers
show a particular affinity for the reticuloendothelial system,
as suggested by high concentrations of sensitiser in the liver
and spleen. Gomer and Dougherty (1979) reported this to be
true for HpD labelled with carbon-14 and tritium in female
DBA/2Ha DD mice bearing a breast cancer. Our results in
this study suggest that mTHPC has similar affinity for the
reticuloendothelial system, especially for periods shortly after
i.v. injection. As issue of vital importance when choosing a
photosensitiser is its relative distribution in the different
organs invaded by, and lying in proximity with, the tumour.
This information is essential when selecting the suitable sen-
sitiser for treating a particular area and estimating the
optimal inj,ection-irradiation interval. Accordingly, the ideal
photosensitiser may be a relative question depending on the
twuour in question and its anatomical location. However, in
order to compare the distribution of different sensitisers it is
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Figure 7 mTHPC retained by each tissue type 48 h post injection as a percentage of the level at 24 h.
important to use a well-defined, standardised experimental tumours confined to, or in close proximity to, muscular
model. organs, earlier irradiation might perhaps be advantageous,
In conclusion, our results suggest that most effective time since the tumour-muscle demarcation does not appear to
interval for PDT varies according to the tumour and accord- improve significantly with time and the overall sensitiser
ing to the tissues surrounding it. The spectra from the concentration is much higher at earlier time points. Coin-
injected animals show that mTHPC is retained with good pared with the results of previous studies by our group on a
selectivity in tumour tissue, as compared with the different number of other photosensitisers, using the same animal and
healthy tissues investigated. Significantly higher chlorin- tumour model and very similar measurement equipment, we
related fluorescence was found at 24 h post injection than at have found mTHPC to exhibit significantly better tumour,
48 h for all measured tissues. Apart from the tumour-muscle muscle selectivity than Photofrin, in addition to the newer
demarcation which remained relatively constant over the two sensitisers BPD-MA, PHE and TSPc.
time intervals investigated (the fluorescence intensities
decreased in the same proportions in muscle and in tumour),
the demarcation between the tumour and the other tissuesn Theautors gratefullyoacknowledge Scotimati for pr
model. ~. _ . h orp hos, earlieru irdationowlegh cta pehaps beutadvantforopro
Incrasesat 48 i. hese results wouldg suggest tfat PT tim viding samples of mTHPCland R. Bonnett and J.C.M. Stewart for
the abdominal or thoracic cavity would probably be safer valuable discussions. This work was supported by the Swedish
and more efficient if pefformed at periods exceeding 48 h Cancer Society, the Swedish National Bhard for Industrial and
post injection in order to allow sensitiser concentrations in Technical Development and the Swedish Research Council for
the liver, spleen and lung to drop. On the other hand, in Engineering Sciences.
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